BCD-261

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameBCD-261
Drug Alias NameBCD-261
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor superfamily member 15
TargetsTumor necrosis factor superfamily member 15
Therapy Area/IndicationsCrohn DiseaseInflammatory Bowel DiseasesColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian FederationMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesSPH-BIOCAD Biopharmaceuticals (SH) Co LtdBIOCAD JSCSPH-Biocad (HK) Ltd
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseInflammatory Bowel DiseasesColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A